Quidel Clocks More Than Three-Fold Jump In COVID-19 Products
Quidel Corp's (NASDAQ:QDEL) Q1 sales more than doubled to $1 billion, beating the consensus of $890 million and meeting management expectations. The company attributed the increase to significantly increased sales of rapid immunoassay products, specifically QuickVue At-Home OTC COVID-19 tests, Sofia Influenza + SARS, and Sofia Influenza tests. "Our diverse suite of assays,…
Benzinga ·
Benzinga
